Presenting at the MedTech Strategist Global Investment & Partnering Summit
Tel-Array’s European Director, Mr. Seamus McAuley, presented at the MedTech Strategist Global Investment & Partnering Virtual Summit 2020 from October 15th to November 20th, 2020. It was a great opportunity to engage and network with the top players in the device industry and showcase Tel-Array’s Spot Profiler.
Patents are in the national examination phase
Tel-Array initiated the national phase of patent applications in 10 jurisdictions of interest in March 2019. All applications have now entered the national examination phase.
Patented technology "innovative" and with "industrial applicability"
Tel-Array filed an international patent application on the Spot Profiler biosensor and cartridge system in September 2017, which was reviewed by the Canadian Patent Office and subsequently published in April 2018.
The International Search Authority (ISA) concludes the technology to be “innovative” and with “industrial applicability”.
National patent applications to be filed in 2019 in select countries of interest.
A-1 Prototype Development Completed
Tel-Array is pleased to announce the completion of the A-1 prototype for its TA Biosensor System. The prototype is currently undergoing vigorous testing in preparation for field and clinical trials.
Meeting with Dr. Saul Isserow
Tel-Array co-founders and management had an insightful meeting with Scientific Advisory Board member, Dr. Saul Isserow to discuss the future of the company's technology and products.
Dr. Isserow is the Director of both Cardiovascular Health at Vancouver General Hospital (VGH) and Cardiology Services at University of British Columbia Hospital (UBC Hospital). He is a leading figure in the cardiology medical field and well-connected with other medical and laboratory specialists.
Tel-Array appreciates the time and support Dr. Isserow provides to the company, especially with respect to Tel-Array's cardiovascular disease test panel. Tel-Array looks forward to continuing the relationship with Dr. Isserow and reaching other members of the medical community.